Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug | GenomeWeb

Quark Pharmaceuticals said this week that it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy in an ongoing Phase I study of QPI-1007, its synthetic siRNA drug candidate for ocular neuroprotection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.